Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.

Gautam BorthakurGiovanni MartinelliEmmanuel RaffouxPatrice ChevallierJörg ChromikAndrew LithioClaire L SmithEunice YuenGerard Joseph OakleyKarim A BenhadjiDaniel J DeAngelo

Published in: Cancer (2020)

Crenigacestat demonstrated limited clinical activity at the recommended dose in adult patients with relapsed/refractory T-ALL/T-LBL.

Keyphrases

acute lymphoblastic leukemia
diffuse large b cell lymphoma
allogeneic hematopoietic stem cell transplantation
low dose
open label
high dose
multiple myeloma
hodgkin lymphoma
study protocol